Cardiac anti-remodelling effects of phosphodiesterase type 5 inhibitors: Afterload-(in)dependent?

Cardiovascular Research

Volumn 82, Issue 1, 2009, Pages 4-6

  Kuhn, Michaela ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GUANYLATE CYCLASE; NATRIURETIC PEPTIDE TYPE C; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

DRUG EFFICACY; DRUG SAFETY; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; HEART AFTERLOAD; HEART EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HEART VENTRICLE REMODELING; HUMAN; LUNG ARTERY PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; VASCULAR SMOOTH MUSCLE;

ADMINISTRATION, ORAL; ANIMALS; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; EXTRACELLULAR MATRIX PROTEINS; FIBROSIS; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; RATS; SULFONES; VENTRICULAR REMODELING;

EID: 62349100891     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp057     Document Type: Editorial

References (17)

1. Hofmann F, Bernhard D, Lukowski R, Weinmeister P. cGMP regulated protein kinases (cGK). Handb Exp Pharmacol 2009;191:137-162.
2. Kuhn M. Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ Res 2003;93:700-709.
3. Kishimoto I, Rossi K, Garbers DL. A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc Natl Acad Sci USA 2001;98:2703-2706.
4. Holtwick R, van Eickels M, Skryabin BV, Baba HA, Bubikat A, Begrow F et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J Clin Invest 2003;111:1399-1407.
5. Kass DA, Champion HC, Beavo JA. Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007;101:1084-1095.
6. Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D et al. Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
7. Salloum FN, Abbate A, Das A, Houser JE, Mudrick CA, Qureshi IZ et al. Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice. Am J Physiol Heart Circ Physiol 2008;294:H1398-H1406.
8. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005;11:214-222.
9. Schäfer S, Ellinghaus P, Janssen W, Kramer F, Lustig K, Milting H et al. Chronic inhibition of phosphodiesterase 5 does not prevent pressure-overload induced right-ventricular remodelling. Cardiovasc Res 2009;82:30-39.
10. Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116:238-248.
11. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45.
12. van Wolferen SA, Boonstra A, Marcus JT, Marques KM, Bronzwaer JG, Postmus PE et al. Right ventricular reverse remodelling after sildenafil in pulmonary arterial hypertension. Heart 2006;92:1860-1861.
13. Andersen A, Nielsen JM, Peters CD, Schou UK, Sloth E, Nielsen-Kudsk JE. Effects of phosphodiesterase-5 inhibition by sildenafil in the pressure overloaded right heart. Eur J Heart Fail 2008;10:1158-1165.
14. Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL et al. Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition. J Mol Cell Cardiol 2009, doi:10.1016/j.yjmcc.2008. 12.008.
15. Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest 2009, doi:101172/JCI35620,1-13.
16. Kaufman BD, Desai M, Reddy S, Osorio JC, Chen JM, Mosca RS et al. Genomic profiling of left and right ventricular hypertrophy in congenital heart disease. J Card Fail 2008;14:760-767.
17. Zaffran S, Kelly RG, Meilhac SM, Buckingham ME, Brown NA. Right ventricular myocardium derives from the anterior heart field. Circ Res 2004;95:261-268.